ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.01
-1.49%
US Tech 100
18,784.40
-4.51%
S&P 500
5,614.56
-2.70%
US Dollar vs CAD
1.44385
0.06%
Bitcoin
79,607.01
1.44%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tenaya Therapeutics Inc (TNYA)

  7. Tenaya Therapeutics Inc (TNYA) News

TNYA

Tenaya Therapeutics (TNYA)

Tenaya Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TNYA
DateTimeSourceHeadlineSymbolCompany
03/10/20258:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
03/10/20258:41PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNYATenaya Therapeutics Inc
03/10/20253:19PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TNYATenaya Therapeutics Inc
03/10/20253:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
03/10/20253:05PMGlobeNewswire Inc.Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
03/04/20253:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
03/04/20253:19PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
03/03/202510:19PMGlobeNewswire Inc.Tenaya Therapeutics Announces Pricing of Public OfferingNASDAQ:TNYATenaya Therapeutics Inc
03/03/20253:16PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
03/03/20253:10PMGlobeNewswire Inc.Tenaya Therapeutics Announces Proposed Public OfferingNASDAQ:TNYATenaya Therapeutics Inc
03/03/20253:04PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TNYATenaya Therapeutics Inc
03/03/20257:00AMGlobeNewswire Inc.Tenaya Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:TNYATenaya Therapeutics Inc
02/07/20257:30PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
02/07/20253:58PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TNYATenaya Therapeutics Inc
02/07/20253:41PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
02/05/202512:23PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TNYATenaya Therapeutics Inc
02/03/20257:30AMGlobeNewswire Inc.Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative MedicineNASDAQ:TNYATenaya Therapeutics Inc
01/28/20257:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
01/28/20254:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
01/13/20258:16AMGlobeNewswire Inc.Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated MilestonesNASDAQ:TNYATenaya Therapeutics Inc
12/17/20246:58AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
12/17/20246:24AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
12/17/20246:00AMGlobeNewswire Inc.Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
12/16/20243:30PMGlobeNewswire Inc.Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024NASDAQ:TNYATenaya Therapeutics Inc
11/25/20247:30AMGlobeNewswire Inc.Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
11/19/20247:00AMGlobeNewswire Inc.Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:TNYATenaya Therapeutics Inc
11/18/20247:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
11/06/20243:20PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
11/06/20243:20PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
11/06/20243:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNYA

Your Recent History

LSE
0Q8G
Seamless Distribution Ab
AMEX
BSJN
Invesco BulletShares 202...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads